On Tuesday, Cerulean Pharma Inc. (NASDAQ:CERU)’s shares declined -4.92%, and closed at $6.18, after a clinical-stage corporation, declared the pricing of an underwritten public offering of 5,840,000 shares of its ordinary stock at a public offering price of $6.00 per share, before underwriting discounts. All of the shares in the offering are being offered by Cerulean. In addition, Cerulean has granted the underwriters an option for a period of 30 days to purchase up to 876,000 additional shares of ordinary stock at the public offering price, less underwriting discounts.
Leerink Partners LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering. Canaccord Genuity Inc., JMP Securities LLC and Wedbush PacGrow are acting as co-managers for the offering.
Cerulean Pharma Inc., a clinical-stage corporation, develops nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States. The corporation’s lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase II clinical trials for the treatment of relapsed renal cell carcinoma and relapsed ovarian cancer; and in Phase Ib clinical trials for the treatment of neoadjuvant rectal cancer, in addition to in Phase II clinical trials for other indications, such as gastric cancer and small cell lung cancer.
athenahealth, Inc. (NASDAQ:ATHN)’s shares dropped -4.85%, and settled at $116.24, during the last trading session on Tuesday, as a new report shows that a year after the Affordable Care Act’s (ACA) coverage expansion provisions took effect, physicians have not practiced a sharp rise in new or sick patients scheduling appointments. The report was prepared by athenahealth, Inc. (ATHN), a leading provider of cloud-based services and mobile applications for medical groups and health systems, and funded by the Robert Wood Johnson Foundation. The 2014 ACAView report provides a comprehensive measurement of the ACA’s influence on health care providers and patients.
The report, which is the first of its kind to examine the influence of the first year of the ACA on physician practices across the country, draws upon near real-time data from a subset of athenahealth’s growing, cloud-based network of more than 62,000 health care providers and 62 million patients. The report investigates core categories related to patient volume, insurance coverage, and payer mix. Top-line findings reveal that:
- New patient volume did not swell during this period; in fact, new patient visits to primary care providers (PCPs) raised very slightly, and were overall no more complex than those in 2013.
- The ACA has reduced the overall proportion of uninsured patients receiving care in physician offices, especially in Medicaid expansion states.
- The number of diagnoses per patient visit also did not raise sharply contrast to the previous year’s data.
athenahealth, Inc., together with its auxiliaries, operates as a business services corporation that provides ongoing billing, clinical-related, and other related services to medical group practices and health systems in the United States.
At the end of Tuesday’s trade, Nordic American Tankers Limited (NYSE:NAT)’s shares dipped -4.68%, and closed at $12.02, hitting new 52-week high of $12.71, as a tanker corporation, on March 27, declared that it has expanded its current credit facility with DNB Bank ASA and Skandinaviska Enskilda Banken AB. The credit facility has been raised from of $60 million to $150 million with maturity in 2020. At this time $35 million have been drawn.
Nordic American Tankers Limited, a tanker corporation, engages in acquiring and chartering double-hull tankers. As of December 31, 2014, it owned 24 Suezmax crude oil tankers, counting two new buildings under construction. The corporation was founded in 1995 and is based in Hamilton, Bermuda.
Genesis Energy LP (NYSE:GEL), ended its Tuesday’s trading session with -4.64% loss, and closed at $44.77, after Genesis Energy, declared the pricing of a registered underwritten public offering of 4,000,000 ordinary units representing limited partner interests at $44.42 per ordinary unit. We granted the underwriters a 30-day option to purchase up to 600,000 additional ordinary units from us. We intend to use the net proceeds from the offering, counting any net proceeds from the underwriters’ exercise of their option to purchase additional ordinary units, for general partnership purposes, counting funding attainments (counting organic growth projects) or repaying a portion of the borrowings outstanding under our revolving credit facility.
Wells Fargo Securities, BofA Merrill Lynch, Citigroup, Deutsche Bank Securities, RBC Capital Markets, Credit Suisse, Raymond James and UBS Investment Bank are acting as joint book-running managers for the offering. Baird, BMO Capital Markets and Janney Montgomery Scott are acting as co-managers. The offering is predictable to settle and close on April 10, 2015, subject to customary closing conditions.
Genesis Energy, L.P. operates in the midstream segment of the oil and gas industry in the Gulf Coast region of the United States. Its Onshore Pipeline Transportation segment transports crude oil and carbon dioxide (CO2). This segment owns 4 onshore crude oil pipeline systems with about 500 miles of pipe located primarily in Alabama, Florida, Louisiana, Mississippi, and Texas; and 2 CO2 pipelines with about 270 miles of pipe.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
